Abstract
Esophageal lichen planus (ELP) is a chronic inflammatory process characterized by apoptotic activity of cytotoxic CD8+ T cells on basal keratinocytes as well as regulatory and helper T cells.1-3 Due to chronic inflammation, malignant transformation may be a concern and has been documented in case reports.4,5 We describe the occurrence of esophageal cancer in ELP patients from a large tertiary patient population.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Chemotherapy, Adjuvant
-
Deglutition Disorders
-
Disease Progression
-
Endoscopic Mucosal Resection
-
Endoscopy, Digestive System
-
Esophageal Diseases / drug therapy
-
Esophageal Diseases / epidemiology
-
Esophageal Diseases / pathology
-
Esophageal Neoplasms / epidemiology*
-
Esophageal Neoplasms / physiopathology
-
Esophageal Neoplasms / therapy
-
Esophageal Squamous Cell Carcinoma / epidemiology*
-
Esophageal Squamous Cell Carcinoma / physiopathology
-
Esophageal Squamous Cell Carcinoma / therapy
-
Esophagectomy
-
Female
-
Glucocorticoids / therapeutic use
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Lichen Planus / drug therapy
-
Lichen Planus / epidemiology*
-
Lichen Planus / pathology
-
Male
-
Middle Aged
-
Radiotherapy, Adjuvant
-
Risk Factors
Substances
-
Glucocorticoids
-
Immunosuppressive Agents